According to MBS’ press release, the BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA). The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range. Read full story
BBI Group Acquires Maine Biotechnology Services
Related Posts
Business Leaders: Deborah Bronk steers Bigelow Lab expansion to boost reach, programming
Deborah Bronk is president, CEO and a senior research scientist at Bigelow Laboratory for Ocean Sciences in East Boothbay, which will...
UNE retains R2 Research status, reinforcing leadership in scientific advancement
The University of New England has retained its status as one of the country’s leading research universities with the recent release...
Maine college students investigate health effects of forever chemicals
Two dozen Maine college students are investigating the public health effects of forever chemicals by using zebrafish as human stand-ins and...